Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Avenciguat in Healthy Males
NCT02694354Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2016
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in diabetic kidney disease (DKD), Portal Hypertension (PH) and systemic sclerosis (SSc) comparing Avenciguat with Placebo (2 arms). Primary endpoint: Number of subjects with drug-related Adverse Events. Started Mar 2016; status: completed.
02
Drugs
avenciguat
03
Conditions
diabetic kidney disease (DKD)Portal Hypertension (PH)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT02694354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02694354.